The Technical Analyst
Genetron Holdings Limited [GTH]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Genetron Holdings Limited Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.12% $4.03
America/New_York / 28 mar 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 127.29 mill |
| EPS: | -3.62 |
| P/E: | -1.110 |
| Earnings Date: | Jan 18, 2024 |
| SharesOutstanding: | 31.62 mill |
| Avg Daily Volume: | 0.0519 mill |
| RATING 2024-03-28 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | n/a | n/a | n/a | n/a | ||
| Asset | n/a | n/a | n/a | n/a | ||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.110 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.06x |
| Company: PE -1.110 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.99 - 4.07 ( +/- 0.89%) |
| ATR Model: 14 days |
Forecast:
16:00 - $4.02
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.02
Forecast 2: 16:00 - $4.02
Forecast 3: 16:00 - $4.02
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.03 (0.12% ) |
| Volume | 0.413 mill |
| Avg. Vol. | 0.0519 mill |
| % of Avg. Vol | 795.55 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GTH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GTH
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
Latest Press Releases
2024-03-28 13:30:00 - Press Release
Genetron Health Announces Completion Of Going Private Transaction
Beijing, march 28, 2024 (globe newswire) -- genetron holdings limited (“genetron health” or the “company”, nasdaq: gth), a leading precision oncology platform company in china that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the “merger”) with genetron new co limited (“merger sub”), pursuant to the previously announced agreement and plan of merger, dated as of october 11, 2023 (the “merger agreement”), among the company, new genetron holding limited (“parent”) and merger sub. as a result of the merger, the company has become a wholly owned subsidiary of parent and will cease to be a publicly traded company.
2024-02-21 06:00:00 - Press Release
Genetron Health Announces Shareholders' Approval Of Merger Agreement
Beijing, feb. 21, 2024 (globe newswire) -- genetron holdings limited (“genetron health” or the “company”, nasdaq: gth), a leading precision oncology platform company in china that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that at an extraordinary general meeting of shareholders (the “egm”) held today, the company's shareholders voted in favor of, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of october 11, 2023 (the “merger agreement”), among the company, new genetron holding limited (“parent”) and genetron new co limited (“merger sub”), pursuant to which, merger sub will be merged with and into the company with the company continuing as the surviving company and becoming a wholly owned subsidiary of parent (the “merger”), the plan of merger (the “plan of merger”) required to be filed with the registrar of companies of the cayman islands, and the transactions contemplated thereby, including the merger.
2024-01-17 06:05:00 - Press Release
Genetron Health To Hold Extraordinary General Meeting Of Shareholders
Beijing, jan. 17, 2024 (globe newswire) -- genetron holdings limited (“genetron health” or the “company”, nasdaq: gth), a leading precision oncology platform company in china that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has called an extraordinary general meeting of shareholders (the “egm”), to be held at on february 21, 2024 at 9:00 a.m. (beijing time) at 1/f, building 11, zone 1, no. 8 life science parkway, changping district, beijing, people's republic of china, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of october 11, 2023 (the “merger agreement”), among the company, new genetron holding limited (“parent”) and genetron new co limited (“merger sub”), and the plan of merger required to be filed with the registrar of companies of the cayman islands (the “plan of merger”) and the transactions contemplated thereby, including the merger (as defined below).
2023-10-11 16:30:00 - Press Release
Genetron Health Enters Into Definitive Merger Agreement For Going Private Transaction
Beijing, oct. 11, 2023 (globe newswire) -- genetron holdings limited (“genetron health” or the “company”, nasdaq: gth), a leading precision oncology platform company in china that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has entered into a definitive agreement and plan of merger (the “merger agreement”) with new genetron holding limited (“parent”) and genetron new co limited (“merger sub”), a wholly-owned subsidiary of parent. pursuant to the merger agreement and subject to the terms and conditions thereof, merger sub will merge with and into the company, with the company continuing as the surviving entity and becoming a wholly-owned subsidiary of parent (the “merger”), in a transaction implying an equity value of the company of approximately us$126...
2022-05-23 16:05:00 - Press Release
Genetron Health To Announce First Quarter 2022 Unaudited Financial Results And Host Investor Call On June 2, 2022
Beijing, may 23, 2022 (globe newswire) -- genetron holdings limited (“genetron health” or the “company”, nasdaq: gth), a leading precision oncology platform company in china that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended march 31, 2022 on june 2, 2022 before the us market open.
Latest News
2023-10-12 09:56:15 - Proactive Investors
Genetron stock rallies on CEO-led deal to go private
Genetron Holdings has announced it will go private through an acquisition by a group of investors led by its co-founder and CEO Sizhen Wang and CICC Healthcare Investment Fund which values the Chinese precision oncology platform at US$126 million. The company's US-listed American Depository Shares (ADSs) jumped 27% in early Thursday trading to $1.1950.
2022-06-02 20:02:01 - Seeking Alpha
Genetron Holdings Limited (GTH) CEO Sizhen Wang on Q1 2022 Results - Earnings Call Transcript
Genetron Holdings Limited (NASDAQ:GTH ) Q1 2022 Earnings Conference Call June 2, 2022 8:30 AM ET Company Participants Evan Xu - Chief Financial Officer Sizhen Wang - Co-Founder, Chairman & Chief Executive Officer Conference Call Participants Yang Huang - Credit Suisse Operator Good morning, and thank you for standing by. Welcome to the First Quarter 2022 Genetron Health Earnings Conference Call.
2022-05-23 16:05:00 - GlobeNewsWire
Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022
BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2022 on June 2, 2022 before the US market open.
2022-03-29 13:08:05 - Seeking Alpha
Genetron Holdings Limited's (GTH) CEO Sizhen Wang on Q4 2021 Results - Earnings Call Transcript
Genetron Holdings Limited's (GTH) CEO Sizhen Wang on Q4 2021 Results - Earnings Call Transcript
2022-03-09 16:05:00 - GlobeNewsWire
Genetron Health to Announce Fourth Quarter and Full Year 2021 Unaudited Financial Results and Host Investor Call on March 29, 2022
BEIJING, March 09, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the fourth quarter and full year ended December 31, 2021 on March 29, 2022 before the US market open.
2022-01-31 08:00:00 - GlobeNewsWire
Genetron Health to Participate in Upcoming Investor Conferences
BEIJING, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will be participating in two upcoming virtual investor conferences.
2021-11-30 14:57:18 - Seeking Alpha
Genetron Holdings Limited (GTH) CEO Sizhen Wang On Q3 2021 Results - Earnings Call Transcript
Genetron Holdings Limited (GTH) CEO Sizhen Wang On Q3 2021 Results - Earnings Call Transcript
2021-09-27 06:00:00 - GlobeNewsWire
Genetron Health and IMPACT Therapeutics Announce Partnership to Drive Development of Synthetic Lethal Product Pipeline
BEIJING, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced a partnership with IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics.
2021-09-16 06:00:00 - GlobeNewsWire
Genetron Health Unveils 13 Cancer Research findings at ESMO Congress 2021
BEIJING, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has partnered with a consortium of 14 top Chinese hospitals to release 13 key research findings at the ESMO 2021 Congress, hosted by the European Society for Medical Oncology. The findings focus on the exploration of genomics amongst the Chinese population, and provide important insights for clinical pathology classification, targeted therapy and immunotherapy strategies, and the clinical management of hereditary colorectal cancer.
2021-09-03 11:07:00 - GlobeNewsWire
Genetron Added to FTSE Russell Global Equity Index Series
BEIJING, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), today announced that Genetron will be added to the below FTSE Global Equity Index Series ("GEIS"), following FTSE's most recent quarterly review. These inclusions will become effective after the market close on Friday, September 17, 2021: